Adverse Drug Reactions and Patient Community

Selected news for the healthcare topic - Adverse Drug Reactions, and the healthcare topic - Patient Community. We have 6 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
9/29/2020 U.S. FDA Approves Pfizer’s XELJANZ (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis ... adverse drug reactions in patients with pcJIA were consistent with those seen in adult rheumatoid arthritis (RA) patients.Please see important safety information below."Many children and adolescents living with polyarticular course juvenile idiopathic arthritis, or pcJIA, are in need of advanced oral treatment options, so we are proud to now offer XELJANZ to this patient community," 4a said Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development. "This ...
9/29/2020 U.S. FDA Approves Pfizers XELJANZ (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis | Financial Buzz ... adverse drug reactions in patients with pcJIA were consistent with those seen in adult rheumatoid arthritis (RA) patients. Please see important safety information below.“Many children and adolescents living with polyarticular course juvenile idiopathic arthritis, or pcJIA, are in need of advanced oral treatment options, so we are proud to now offer XELJANZ to this patient community,” 4a said Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development ...
9/28/2020 U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis | Business Wire Business Wire ... adverse drug reactions in patients with pcJIA were consistent with those seen in adult rheumatoid arthritis (RA) patients. Please see important safety information below.“Many children and adolescents living with polyarticular course juvenile idiopathic arthritis, or pcJIA, are in need of advanced oral treatment options, so we are proud to now offer XELJANZ to this patient community,” 4a said Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development ...
9/28/2020 ... adverse drug reactions in patients with pcJIA were consistent with those seen in adult rheumatoid arthritis (RA) patients. Please see important safety information below.“Many children and adolescents living with polyarticular course juvenile idiopathic arthritis, or pcJIA, are in need of advanced oral treatment options, so we are proud to now offer XELJANZ to this patient community,” 4a said Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development ...
9/28/2020 U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis BioSpace ... adverse drug reactions in patients with pcJIA were consistent with those seen in adult rheumatoid arthritis (RA) patients. Please see important safety information below.“Many children and adolescents living with polyarticular course juvenile idiopathic arthritis, or pcJIA, are in need of advanced oral treatment options, so we are proud to now offer XELJANZ to this patient community,” 4a said Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development ...
9/28/2020 U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis Business Wire ... adverse drug reactions in patients with pcJIA were consistent with those seen in adult rheumatoid arthritis (RA) patients. Please see important safety information below.“Many children and adolescents living with polyarticular course juvenile idiopathic arthritis, or pcJIA, are in need of advanced oral treatment options, so we are proud to now offer XELJANZ to this patient community,” 4a said Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development ...